Blau Farmaceutica expects third-quarter improvement: what it means for Blau Farmaceutica stock

Published on 10/25/2026 at 02:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter improvement is expected. The first half delivered BRL 922 million for Blau Farmaceutica stock, up 10 percent year over year.

Operating improvement and cash conversion

A sector preview dated October 19, 2026, expected better operating performance for the third quarter of 2026.
Revenue reached BRL 922 million in the first half of 2026, up 10 percent year over year.
Recurring EBITDA reached BRL 230 million in the first half of 2026, with a 24.9 percent margin.
Blau Farmaceutica is scheduled to release third-quarter results on November 11, 2026.

Blau Farmaceutica, BRBLAUACNOR8, Illustration mit AI erstellt.

Blau Farmaceutica (ISIN BRBLAUACNOR8) is expected to improve its operating performance in the third quarter of 2026, while first-half revenue had already reached BRL 922 million, up 10 percent from the same period of 2025. Guia do Investidor reported the sector preview on October 19, 2026.

Three dated signals shape the setup

The chronology starts with a BRL 17.5 million interest-on-equity distribution approved on September 24, 2026. ADVFN said the payment was scheduled for October 8, 2026, after a September 29, 2026 record date. The October 19, 2026 preview then pointed to better third-quarter operations, making the operating outlook the latest dated signal.

What could improve in the third quarter?

The answer is operating leverage. In its report dated August 11, 2026, Blau Farmaceutica reported recurring EBITDA of BRL 230 million for the first half of 2026, up 12 percent year over year, while the recurring EBITDA margin reached 24.9 percent, up from 24.5 percent. The same release reported operating cash flow of BRL 212 million, compared with BRL 88 million in the first half of 2025. The counterweight is accounting profit: net income fell 40 percent to BRL 92 million, affected by foreign-exchange effects and non-recurring items.

Next date is November 11

TraderNews listed November 11, 2026, as the scheduled date for third-quarter results. The release should provide the next comparison for revenue growth, recurring EBITDA margin and cash generation.

Stock context remains tied to execution

The latest available B3 quote stood at BRL 12.33 on October 23, 2026, while the 52-week range was BRL 8.28 to BRL 14.50. Market capitalization was BRL 2.8 billion as of October 23, 2026. For investors, the central test is whether new production lines and stronger cash conversion can support the 24.9 percent recurring EBITDA margin.